IMM-101 + cyclophosphamide

IMM-101 + cyclophosphamide is a combination immunotherapy regimen investigated for its synergistic anti-tumor effects in advanced solid malignancies. IMM-101 is a systemic immune modulator consisting of a heat-killed preparation of the environmental bacterium *Mycobacterium obuense* (NCTC 13365). It acts primarily as a Toll-like receptor 2 (TLR2) agonist, stimulating the innate immune system by activating dendritic cells and natural killer cells, which in turn promotes a Th1-biased adaptive immune response. Cyclophosphamide is a nitrogen mustard alkylating agent that, when used in this combination at low metronomic doses, functions as an immunomodulator by selectively depleting regulatory T cells (Tregs). This depletion reduces immunosuppression within the tumor microenvironment, thereby enhancing the efficacy of the IMM-101-induced immune response. The combination has been explored in clinical trials for various cancers, including pancreatic cancer, melanoma, and colorectal cancer, aiming to improve overall survival and quality of life.

Other names

heat-killed Mycobacterium obuense + cyclophosphamideIMM-101 and metronomic cyclophosphamideIMM101 and metronomic cyclophosphamideIMM 101 and metronomic cyclophosphamide